BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 31351074)

  • 1. Drug discovery for chagas disease: A viewpoint.
    Kratz JM
    Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in Chagas Disease Drug Discovery: A Review.
    Paucar R; Moreno-Viguri E; Pérez-Silanes S
    Curr Med Chem; 2016; 23(28):3154-3170. PubMed ID: 27356544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
    Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
    Filardi LS; Brener Z
    Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current drug therapy and pharmaceutical challenges for Chagas disease.
    Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
    Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential new clinical therapies for Chagas disease.
    Bustamante JM; Tarleton RL
    Expert Rev Clin Pharmacol; 2014 May; 7(3):317-25. PubMed ID: 24716790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature.
    Molina I; Perin L; Aviles AS; de Abreu Vieira PM; da Silva Fonseca K; Cunha LM; Carneiro CM
    Acta Trop; 2020 Jan; 201():105218. PubMed ID: 31610148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A flow cytometer-based method to simultaneously assess activity and selectivity of compounds against the intracellular forms of Trypanosoma cruzi.
    Miranda CG; Solana ME; Curto MLA; Lammel EM; Schijman AG; Alba Soto CD
    Acta Trop; 2015 Dec; 152():8-16. PubMed ID: 26272680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy of Chagas' disease: status and new developments.
    Cerecetto H; González M
    Curr Top Med Chem; 2002 Nov; 2(11):1187-213. PubMed ID: 12171581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
    Murcia L; Carrilero B; Albajar Viñas P; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
    [No Abstract]   [Full Text] [Related]  

  • 11. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
    Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
    Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of a novel compound, (e)-1-(4'-bromo-4-biphenylyl)-1-(4-chlorophenyl)-3-dimethylaminoprop-1-ene against Trypanosoma cruzi in mice.
    Barrett PA; Beveridge E; Bull D; Caldwell IC; Islip PJ; Neal RA; Woods NC
    Experientia; 1982 Mar; 38(3):338-9. PubMed ID: 6804255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Discovery for Paediatric Chagas Disease.
    Thota S; Morel CM
    Mini Rev Med Chem; 2018; 18(9):776-780. PubMed ID: 26202205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
    Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
    Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.
    Urbina JA
    J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on benznidazole for the treatment of patients with Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenge of Chagas' disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi.
    de Castro SL
    Acta Trop; 1993 Apr; 53(2):83-98. PubMed ID: 8098901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of Chagas' disease].
    Apt W
    Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
    [No Abstract]   [Full Text] [Related]  

  • 19. Chagas disease: Present status of pathogenic mechanisms and chemotherapy.
    Maya JD; Orellana M; Ferreira J; Kemmerling U; López-Muñoz R; Morello A
    Biol Res; 2010; 43(3):323-31. PubMed ID: 21249304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developments on treatment of Chagas disease - from discovery to current times.
    Custodio Leite TO
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2576-2586. PubMed ID: 30964186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.